MDX Meldex

    RNS Number : 2589Z
  Meldex International PLC
  17 July 2008
   

    For Immediate Release                                                                                                            17 July
2008

    Meldex International plc

    Potential Offer

    London, UK: Meldex International plc ("the Company"), the specialty pharmaceutical and healthcare company, announces that Steve Martin,
the Chief Development Officer and Board member of the Company, has made an approach to the Board of Directors ("the Board") seeking
permission to explore the possibility of making an offer for the Company. 

    There can be no guarantee that this approach will lead to an offer being made for the issued ordinary share capital of the Company, or
that any transaction will be recommended by the Board or consummated.

    An Independent Committee of the Board has been formed for the purposes of considering any and all offers made. A further announcement
will be made in due course.


    For further information: 

 Meldex International plc        + 44 (0) 20 7098 9880 
                                  
 Nomura Code Securities Limited  + 44 (0) 20 7776 1200
  
 Corfin Communications           + 44 (0) 20 7977 0020

    Houlihan Lokey                                                            + 44 (0) 20 7839 3355


    The City Code on Takeovers and Mergers (the "City Code")

    1) Rule 2.10 of the City Code

    In accordance with Rule 2.10 of the City Code, the Company confirms that it has 213,866,433 ordinary shares of 1p each in issue under
the ISIN code GB0032681628. 

    2) Dealing Disclosure Requirements 

    Under the provisions of Rule 8.3 of the City Code, if any person is, or becomes, "interested" (directly or indirectly) in 1% or more of
any class of "relevant securities" of Meldex International plc, all "dealings" in any "relevant securities" of that company (including by
means of an option in respect of, or a derivative referenced to, any such "relevant securities") must be publicly disclosed by no later than
3.30pm (London time) on the London business day following the date of the relevant transaction. This requirement will continue until the
date on which the offer becomes, or is declared, unconditional as to acceptances, lapses or is otherwise withdrawn or on which the "offer
period" otherwise ends. 

    If two or more persons act together pursuant to an agreement or understanding, whether
    formal or informal, to acquire an "interest" in "relevant securities" of Meldex International plc, they will be deemed to be a single
person for the purpose of Rule 8.3.

    Under the provisions of Rule 8.1 of the City Code, all "dealings" in "relevant securities" of Meldex International plc by Meldex
International plc, or by any of their respective "associates", must be disclosed by no later than 12.00 noon (London time) on the London
business day following the date of the relevant transaction.

    A disclosure table, giving details of the companies in whose "relevant securities"
    "dealings" should be disclosed, and the number of such securities in issue, can be
    found on the Takeover Panel's website at www.thetakeoverpanel.org.uk.

    "Interests in securities" arise, in summary, when a person has long economic exposure, whether conditional or absolute, to changes in
the price of securities. In particular, a person will be treated as having an "interest" by virtue of the ownership or control of
securities, or by virtue of any option in respect of, or derivative referenced to, securities.

    Terms in quotation marks are defined in the City Code, which can also be found on the Panel's website. If you are in any doubt as to
whether or not you are required to
    disclose a "dealing" under Rule 8, you should consult the Panel.


    About Meldex International plc

    Meldex International plc is an innovative specialty pharmaceutical and OTC product company. Listed on London's AIM in May 2003, the
Company has over 80 patents granted or in application within 24 patent families and has product development agreements and strategic
alliances with several global healthcare companies. Meldex has acquired sales and marketing resources within Europe and the US as a launch
mechanism for its own pharmaceutical products. Meldex acquired the Melbrosin business in June 2007 for a consideration of up to EUR35m.
Melbrosin's focus is on consumer over the counter health care products based on substances of natural and plant origin which are developed
into consumer orientated brands and then scaled, produced and distributed by Melbrosin. The Melbrosin business complements the prescription
pharmaceutical sales and marketing business created and expanded in 2006. 

    The business continues to develop innovative delivery mechanisms enhancing both its own product range and those of selected partners
using its proprietary XGEL* polymer technology. For further information please go to www.meldexinternational.com 


This information is provided by RNS
The company news service from the London Stock Exchange
 
  END 
 
OFDBDLBFVDBLBBF

Meldex (LSE:MDX)
Historical Stock Chart
From Sep 2024 to Oct 2024

Meldex (LSE:MDX)
Historical Stock Chart
From Oct 2023 to Oct 2024